JMP Securities Lowers PolyPid (NASDAQ:PYPD) Price Target to $14.00

PolyPid (NASDAQ:PYPD) had its price target dropped by investment analysts at JMP Securities from $16.00 to $14.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. JMP Securities’ price objective would indicate a potential upside of 322.96% from the company’s previous close.

PYPD has been the subject of a number of other research reports. HC Wainwright boosted their price target on PolyPid from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, June 9th. Roth Capital started coverage on PolyPid in a research report on Thursday, June 5th. They issued a “buy” rating and a $9.00 target price on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, PolyPid has an average rating of “Buy” and a consensus target price of $11.80.

PolyPid Price Performance

Shares of NASDAQ:PYPD opened at $3.31 on Tuesday. The firm has a 50 day moving average of $2.88 and a 200-day moving average of $2.92. PolyPid has a 12 month low of $2.30 and a 12 month high of $4.49. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 4.43. The stock has a market capitalization of $33.73 million, a PE ratio of -0.77 and a beta of 1.25.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.10. On average, equities research analysts predict that PolyPid will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Rosalind Advisors Inc. increased its holdings in PolyPid by 50.6% in the 4th quarter. Rosalind Advisors Inc. now owns 1,022,521 shares of the company’s stock worth $3,108,000 after purchasing an additional 343,353 shares in the last quarter. AIGH Capital Management LLC grew its holdings in shares of PolyPid by 13.6% during the first quarter. AIGH Capital Management LLC now owns 940,381 shares of the company’s stock worth $2,548,000 after purchasing an additional 112,514 shares during the last quarter. Finally, J. Goldman & Co LP acquired a new position in shares of PolyPid in the fourth quarter valued at approximately $391,000. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.